Editas Medicine Inc. (NASDAQ: EDIT) started the day on November 24, 2021, with a price decrease of -2.09% at $33.30. During the day, the stock rose to $34.01 and sunk to $32.53 before settling in for the price of $34.01 at the close. Taking a more long-term approach, EDIT posted a 52-week range of $28.71-$99.95.
The Healthcare sector firm’s twelve-monthly sales growth has been 123.40% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 0.70%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 26.00%. This publicly-traded company’s shares outstanding now amounts to $68.22 million, simultaneously with a float of $68.18 million. The organization now has a market capitalization sitting at $2.34 billion. At the time of writing, stock’s 50-day Moving Average stood at $41.60, while the 200-day Moving Average is $44.46.
Editas Medicine Inc. (EDIT) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Editas Medicine Inc.’s current insider ownership accounts for 0.20%, in contrast to 74.50% institutional ownership. According to the most recent insider trade that took place on Nov 12, this organization’s EVP/Chief Medical Officer sold 1,568 shares at the rate of 38.33, making the entire transaction reach 60,101 in total value, affecting insider ownership by 18,432. Preceding that transaction, on Nov 09, Company’s EVP, Chief Business Officer sold 287 for 40.61, making the whole transaction’s value amount to 11,655. This particular insider is now the holder of 28,026 in total.
Editas Medicine Inc. (EDIT) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 9/29/2021, the organization reported -$0.57 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.82) by $0.25. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.78 per share during the current fiscal year.
Editas Medicine Inc.’s EPS increase for this current 12-month fiscal period is 26.00% and is forecasted to reach -3.33 in the upcoming year.
Editas Medicine Inc. (NASDAQ: EDIT) Trading Performance Indicators
Let’s observe the current performance indicators for Editas Medicine Inc. (EDIT). It’s Quick Ratio in the last reported quarter now stands at 11.10. The Stock has managed to achieve an average true range (ATR) of 1.84. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 95.39.
In the same vein, EDIT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.25, a figure that is expected to reach -0.81 in the next quarter, and analysts are predicting that it will be -3.33 at the market close of one year from today.
Technical Analysis of Editas Medicine Inc. (EDIT)
If we take a close look at the recent performances of Editas Medicine Inc. (NASDAQ: EDIT), its last 5-days Average volume was 1.09 million that shows plunge from its year to date volume of 1.89 million. During the previous 9 days, stock’s Stochastic %D was recorded 15.47% While, its Average True Range was 1.90.
Raw Stochastic average of Editas Medicine Inc. (EDIT) in the period of the previous 100 days is set at 2.93%, which indicates a major fall in contrast to 11.99% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 54.85% that was lower than 76.04% volatility it exhibited in the past 100-days period.